Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00769392 · ClinicalTrials.gov registry record · NA

Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection

A NA study of Macular Degeneration, sponsored by Lahey Clinic.

Completed
Registry status
NA
Development phase
28
Enrollment target
3
Study locations

NCT00769392: Completed NA study of Macular Degeneration, sponsored by Lahey Clinic.

NCT00769392 is a NA study of Macular Degeneration that has completed, run by Lahey Clinic. The registered enrollment target is 28 participants, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00769392, a NA study of Macular Degeneration, has completed, sponsored by Lahey Clinic.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
3
Study locations

Study Summary

This study is designed to compare four currently used types of anesthesia used prior to intravitreal injection in order to evaluate the most effective method of anesthesia in reducing pain and discomfort associated with intravitreal injections.

Primary Outcome

Discomfort Associated With the Intravitreal Injection using a Subjective Analog Pain Scale (0-10); no pain (0) and severe pain (10)

Conditions Studied

Interventions

  • DRUG Proparacaine Ophthalmic
  • DRUG Tetracaine Ophthalmic
  • DRUG Lidocaine 4%
  • DRUG Lidocaine 2% Injectable Solution

Study Locations (3)

Massachusetts

  • Lahey Clinic Arlington - Arlington
  • Lahey Clinic, Inc. - Burlington
  • Lahey Clinic Northshore - Peabody

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2008-09
Est. Completion 2009-08-12
Phase NA
Lahey Clinic

43 total trials

What the finished NCT00769392 record still lists

NCT00769392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 4 interventions - of which Proparacaine Ophthalmic is the first listed.

NCT00769392 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00769392 about?

NCT00769392 is a clinical study titled "Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection". This study is designed to compare four currently used types of anesthesia used prior to intravitreal injection in order to evaluate the most effective method of anesthesia in reducing pain and discomfort associated with intravitreal injections.

What is the current status of trial NCT00769392?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2008-09. Estimated completion is 2009-08-12.

What conditions does trial NCT00769392 study?

This clinical trial studies the following conditions: Macular Degeneration.

What interventions are being tested in trial NCT00769392?

The interventions under investigation include: Proparacaine Ophthalmic (DRUG), Tetracaine Ophthalmic (DRUG), Lidocaine 4% (DRUG), Lidocaine 2% Injectable Solution (DRUG).

Who is sponsoring clinical trial NCT00769392?

This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00769392 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00769392's enrollment target sits among peer trials

28 22nd of 26 higher than 5 of 26 other Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00769392, the US trial registry maintained by the National Library of Medicine. NCT00769392 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.